---
document_datetime: 2025-12-29 11:34:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/infanrix-hexa.html
document_name: infanrix-hexa.html
version: success
processing_time: 0.1312659
conversion_datetime: 2025-12-30 12:00:15.435447
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Infanrix Hexa

[RSS](/en/individual-human-medicine.xml/65960)

##### Authorised

This medicine is authorised for use in the European Union

diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type-b (Hib) conjugate vaccine (adsorbed) Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Infanrix Hexa](#news-on)
- [More information on Infanrix Hexa](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Infanrix hexa is a vaccine used to protect infants from six weeks of age and toddlers against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis (polio) and diseases such as bacterial meningitis caused by the bacterium *Haemophilus influenzae* type b (Hib).

Infanrix hexa contains the following active substances:

- toxoids (chemically weakened toxins) from diphtheria and tetanus;
- parts of *Bordetella pertussis* ( *pertussis* , a bacterium that causes whooping cough);
- parts of the hepatitis B virus;
- inactivated polioviruses;
- polysaccharides (sugars) from Hib.

Expand section

Collapse section

## How is Infanrix hexa used?

Infanrix hexa is given by deep injection into a muscle. The vaccination schedule for Infanrix hexa is a course of 2 or 3 doses, given at least 1 month apart, according to official recommendations, usually in the first 6 months of life. Subsequent injections should be given in different areas.

A booster dose of Infanrix hexa or a similar vaccine should be given at least 6 months after the last dose of the initial course. The choice of booster vaccine depends on official recommendations.

The vaccine can only be obtained with a prescription. For more information about using Infanrix hexa, see the package leaflet or contact your doctor or pharmacist.

## How does Infanrix hexa work?

Infanrix hexa is a vaccine that protects against a range of infections. Vaccines work by 'teaching' the immune system (the body's natural defences) to defend the body against the infections.

When a child is given the vaccine, the immune system recognises the parts of the bacteria and viruses in the vaccine as 'foreign' and makes antibodies against them. The immune system will then be able to produce antibodies more quickly when the person comes into contact with the bacteria or viruses. This helps to protect against the diseases that these bacteria and viruses cause.

The vaccine is 'adsorbed'. This means that the active substances are fixed onto aluminium compounds, to stimulate a better response.

## What benefits of Infanrix hexa have been shown in studies?

Infanrix hexa has been studied in nine studies, involving a total of almost 5,000 children aged between 6 weeks and 2 years. Over 3,000 of the children received a course of vaccination with Infanrix hexa. The effects of Infanrix hexa were compared with those of separate vaccines containing the same active substances. The main measure of effectiveness was the production of protective antibodies.

Results of the studies taken together showed that a course of injections with Infanrix hexa was as effective at producing protective levels of antibodies as giving separate vaccines containing the same active substances. Overall, between 95 and 100% of the children had antibodies to diphtheria, tetanus, pertussis, hepatitis B virus, polioviruses, and Hib, 1 month after the vaccination course.

An additional five studies looked at the effects of a booster vaccination with Infanrix hexa. These studies showed that booster vaccinations with Infanrix hexa were as effective as giving separate vaccines containing the same active substances 1 month after the booster vaccination.

## What is the risk associated with Infanrix hexa?

For the full list of side effects and restrictions with Infanrix hexa, see the package leaflet.

The most common side effects with Infanrix hexa (seen in more than 1 in 10 doses of the vaccine) include swelling, pain and redness at the injection site, loss of appetite, fever of 38°C or higher, sleepiness, abnormal crying, irritability and restlessness.

Infanrix hexa must not be used in infants who are hypersensitive (allergic) to any of the active substances, to any of the other ingredients of the vaccine, or to neomycin and polymyxin (antibiotics) and formaldehyde. It must not be used in infants who have had an allergic reaction to a vaccine containing diphtheria, tetanus, pertussis, hepatitis B, polio or Hib. Infanrix hexa must not be used in infants who have had encephalopathy (brain disease) of unknown cause within 7 days of receiving a pertussis vaccine. Infanrix hexa should be postponed in infants with a severe sudden fever.

## Why is Infanrix hexa approved?

Infanrix hexa has been shown to trigger the production of protective levels of antibodies against diphtheria, tetanus, pertussis, hepatitis B virus, polioviruses, and Hib. The side effects of Infanrix hexa are similar to those of other vaccines used to prevent these conditions and are considered acceptable. The European Medicines Agency therefore decided that Infanrix hexa's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Infanrix hexa?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Infanrix hexa have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Infanrix hexa are continuously monitored. Suspected side effects reported with Infanrix hexa are carefully evaluated and any necessary action taken to protect patients.

## Other information about Infanrix hexa:

Infanrix hexa received a marketing authorisation valid throughout the EU on 23 October 2000.

Infanrix Hexa : EPAR - Medicine overview

Reference Number: EMA/336137/2024

English (EN) (163 KB - PDF)

**First published:** 23/12/2008

**Last updated:** 04/09/2024

[View](/en/documents/overview/infanrix-hexa-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-922)

български (BG) (177.65 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/bg/documents/overview/infanrix-hexa-epar-medicine-overview_bg.pdf)

español (ES) (143.42 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/es/documents/overview/infanrix-hexa-epar-medicine-overview_es.pdf)

čeština (CS) (179.61 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/cs/documents/overview/infanrix-hexa-epar-medicine-overview_cs.pdf)

dansk (DA) (146.04 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/da/documents/overview/infanrix-hexa-epar-medicine-overview_da.pdf)

Deutsch (DE) (149.53 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/de/documents/overview/infanrix-hexa-epar-medicine-overview_de.pdf)

eesti keel (ET) (143.92 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/et/documents/overview/infanrix-hexa-epar-medicine-overview_et.pdf)

ελληνικά (EL) (174.43 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/el/documents/overview/infanrix-hexa-epar-medicine-overview_el.pdf)

français (FR) (147.21 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/fr/documents/overview/infanrix-hexa-epar-medicine-overview_fr.pdf)

hrvatski (HR) (174.45 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/hr/documents/overview/infanrix-hexa-epar-medicine-overview_hr.pdf)

italiano (IT) (144.31 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/it/documents/overview/infanrix-hexa-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (185.43 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/lv/documents/overview/infanrix-hexa-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (178.64 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/lt/documents/overview/infanrix-hexa-epar-medicine-overview_lt.pdf)

magyar (HU) (168.11 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/hu/documents/overview/infanrix-hexa-epar-medicine-overview_hu.pdf)

Malti (MT) (195.12 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/mt/documents/overview/infanrix-hexa-epar-medicine-overview_mt.pdf)

Nederlands (NL) (146.02 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/nl/documents/overview/infanrix-hexa-epar-medicine-overview_nl.pdf)

polski (PL) (181.63 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/pl/documents/overview/infanrix-hexa-epar-medicine-overview_pl.pdf)

português (PT) (145.68 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/pt/documents/overview/infanrix-hexa-epar-medicine-overview_pt.pdf)

română (RO) (173.48 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/ro/documents/overview/infanrix-hexa-epar-medicine-overview_ro.pdf)

slovenčina (SK) (167.06 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/sk/documents/overview/infanrix-hexa-epar-medicine-overview_sk.pdf)

slovenščina (SL) (176.48 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/sl/documents/overview/infanrix-hexa-epar-medicine-overview_sl.pdf)

Suomi (FI) (143.17 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/fi/documents/overview/infanrix-hexa-epar-medicine-overview_fi.pdf)

svenska (SV) (142.85 KB - PDF)

**First published:**

23/12/2008

**Last updated:**

04/09/2024

[View](/sv/documents/overview/infanrix-hexa-epar-medicine-overview_sv.pdf)

## Product information

Infanrix Hexa : EPAR - Product Information

English (EN) (578.31 KB - PDF)

**First published:** 26/11/2008

**Last updated:** 04/09/2024

[View](/en/documents/product-information/infanrix-hexa-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-705)

български (BG) (698.93 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/bg/documents/product-information/infanrix-hexa-epar-product-information_bg.pdf)

español (ES) (556.5 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/es/documents/product-information/infanrix-hexa-epar-product-information_es.pdf)

čeština (CS) (669.17 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/cs/documents/product-information/infanrix-hexa-epar-product-information_cs.pdf)

dansk (DA) (558.77 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/da/documents/product-information/infanrix-hexa-epar-product-information_da.pdf)

Deutsch (DE) (569.01 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/de/documents/product-information/infanrix-hexa-epar-product-information_de.pdf)

eesti keel (ET) (608.33 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/et/documents/product-information/infanrix-hexa-epar-product-information_et.pdf)

ελληνικά (EL) (756.37 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/el/documents/product-information/infanrix-hexa-epar-product-information_el.pdf)

français (FR) (675.58 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/fr/documents/product-information/infanrix-hexa-epar-product-information_fr.pdf)

hrvatski (HR) (598.39 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/hr/documents/product-information/infanrix-hexa-epar-product-information_hr.pdf)

íslenska (IS) (556.54 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/is/documents/product-information/infanrix-hexa-epar-product-information_is.pdf)

italiano (IT) (631.29 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/it/documents/product-information/infanrix-hexa-epar-product-information_it.pdf)

latviešu valoda (LV) (621.58 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/lv/documents/product-information/infanrix-hexa-epar-product-information_lv.pdf)

lietuvių kalba (LT) (580.42 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/lt/documents/product-information/infanrix-hexa-epar-product-information_lt.pdf)

magyar (HU) (701.41 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/hu/documents/product-information/infanrix-hexa-epar-product-information_hu.pdf)

Malti (MT) (780.17 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/mt/documents/product-information/infanrix-hexa-epar-product-information_mt.pdf)

Nederlands (NL) (521.73 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/nl/documents/product-information/infanrix-hexa-epar-product-information_nl.pdf)

norsk (NO) (543.42 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/no/documents/product-information/infanrix-hexa-epar-product-information_no.pdf)

polski (PL) (668.68 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/pl/documents/product-information/infanrix-hexa-epar-product-information_pl.pdf)

português (PT) (592.45 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/pt/documents/product-information/infanrix-hexa-epar-product-information_pt.pdf)

română (RO) (645.72 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/ro/documents/product-information/infanrix-hexa-epar-product-information_ro.pdf)

slovenčina (SK) (603.18 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/sk/documents/product-information/infanrix-hexa-epar-product-information_sk.pdf)

slovenščina (SL) (602.48 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/sl/documents/product-information/infanrix-hexa-epar-product-information_sl.pdf)

Suomi (FI) (561.52 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/fi/documents/product-information/infanrix-hexa-epar-product-information_fi.pdf)

svenska (SV) (539.68 KB - PDF)

**First published:**

26/11/2008

**Last updated:**

04/09/2024

[View](/sv/documents/product-information/infanrix-hexa-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0340/G 01/08/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Infanrix Hexa : EPAR - All Authorised presentations

English (EN) (23.45 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 15/01/2020

[View](/en/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-807)

български (BG) (50.57 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/bg/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_bg.pdf)

español (ES) (26.47 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/es/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_es.pdf)

čeština (CS) (38.23 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/cs/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (31.23 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/da/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (19.76 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/de/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (51.46 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/et/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (45.6 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/el/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_el.pdf)

français (FR) (24.21 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/fr/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (36.97 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/hr/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (39.35 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/is/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_is.pdf)

italiano (IT) (26.46 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/it/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (42.62 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/lv/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (40.96 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/lt/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (35.08 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/hu/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (40.1 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/mt/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (24.21 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/nl/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (26.8 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/no/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_no.pdf)

polski (PL) (48.6 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/pl/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_pl.pdf)

português (PT) (26.06 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/pt/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_pt.pdf)

română (RO) (57.34 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/ro/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (40.66 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/sk/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (38.17 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/sl/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (25.16 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/fi/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (49.39 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

15/01/2020

[View](/sv/documents/all-authorised-presentations/infanrix-hexa-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Infanrix Hexa Active substance

- Diphtheria toxoid
- tetanus toxoid
- Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin)
- hepatitis B surface antigen
- poliovirus (inactivated) (type-1 (Mahoney strain), type-2 (MEF-1 strain), type-3 (Saukett strain))
- Haemophilus influenzae type b polysaccharide

International non-proprietary name (INN) or common name diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type-b (Hib) conjugate vaccine (adsorbed) Therapeutic area (MeSH)

- Hepatitis B
- Tetanus
- Immunization
- Meningitis, Haemophilus
- Whooping Cough
- Poliomyelitis
- Diphtheria

Anatomical therapeutic chemical (ATC) code J07CA09

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

Infanrix hexa is indicated for primary and booster vaccination of infants from the age of 6 weeks and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b. The use of Infanrix hexa should be in accordance with official recommendations.

## Authorisation details

EMA product number EMEA/H/C/000296 Marketing authorisation holder

GlaxoSmithKline Biologicals S.A.

Rue de l'Institut, 89

Opinion adopted 29/06/2000 Marketing authorisation issued 23/10/2000 Revision 48

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Infanrix Hexa : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (704.53 KB - PDF)

**First published:** 26/11/2008

**Last updated:** 04/09/2024

[View](/en/documents/procedural-steps-after/infanrix-hexa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

CHMP post-authorisation summary of positive opinion for Infanrix Hexa (II-340-G)

Adopted

Reference Number: EMA/CHMP/291491/2024

English (EN) (142.08 KB - PDF)

**First published:** 28/06/2024

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-infanrix-hexa-ii-340-g_en.pdf)

Infanrix hexa-H-C-296-P46-135 : EPAR - Assessment report

Adopted

Reference Number: EMA/361395/2023

English (EN) (1.37 MB - PDF)

**First published:** 21/09/2023

**Last updated:** 21/09/2023

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-135-epar-assessment-report_en.pdf)

Infanrix Hexa-H-C-296-P46-131 : EPAR - Assessment report

Adopted

Reference Number: EMA/496745/2020

English (EN) (2.69 MB - PDF)

**First published:** 15/10/2020

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-131-epar-assessment-report_en.pdf)

Infanrix Hexa-H-C-296-P46-132 : EPAR - Assessment report

Adopted

Reference Number: EMA/496744/2020

English (EN) (1.88 MB - PDF)

**First published:** 15/10/2020

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-132-epar-assessment-report_en.pdf)

Infanrix Hexa-H-C-296-II-275 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/496743/2020

English (EN) (3.12 MB - PDF)

**First published:** 15/10/2020

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-ii-275-epar-assessment-report-variation_en.pdf)

Infanrix Hexa-H-C-296-P46-130 : EPAR - Assessment report

Adopted

Reference Number: EMA/765993/2018

English (EN) (373.66 KB - PDF)

**First published:** 31/10/2018

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-130-epar-assessment-report_en.pdf-0)

Infanrix Hexa-H-C-296-P46-128 : EPAR - Assessment Report

Adopted

Reference Number: EMA/216598/2018

English (EN) (273.92 KB - PDF)

**First published:** 11/04/2018

**Last updated:** 11/04/2018

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-128-epar-assessment-report_en.pdf)

Infanrix Hexa-H-C-296-P46-126 : EPAR - Assessment Report

Adopted

Reference Number: EMA/288302/2017

English (EN) (894.34 KB - PDF)

**First published:** 01/06/2017

**Last updated:** 01/06/2017

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-126-epar-assessment-report_en.pdf)

Infanrix Hexa-H-C-296-P46-121 : EPAR - Assessment Report

Adopted

Reference Number: EMA/793306/2016

English (EN) (625.9 KB - PDF)

**First published:** 06/02/2017

**Last updated:** 06/02/2017

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-121-epar-assessment-report_en.pdf)

Infanrix hexa-H-C-296-P46-123: EPAR - Assessment report

Adopted

English (EN) (183.23 KB - PDF)

**First published:** 08/12/2016

**Last updated:** 08/12/2016

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-123-epar-assessment-report_en.pdf)

Infanrix Hexa-H-C-296-P46-124 : EPAR - Assessment report

Adopted

English (EN) (561.43 KB - PDF)

**First published:** 30/11/2016

**Last updated:** 30/11/2016

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-124-epar-assessment-report_en.pdf)

Infanrix Hexa-H-C-296-P46-120 : EPAR - Assessment Report

Adopted

Reference Number: EMA/719044/2016

English (EN) (716.04 KB - PDF)

**First published:** 14/11/2016

**Last updated:** 14/11/2016

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-120-epar-assessment-report_en.pdf)

Infanrix Hexa-H-C-296-P46-0119 : EPAR - Assessment Report

Adopted

Reference Number: EMA/549010/2016

English (EN) (858.78 KB - PDF)

**First published:** 12/08/2016

**Last updated:** 12/08/2016

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-0119-epar-assessment-report_en.pdf)

Infanrix Hexa-H-C-296-P46-117 : EPAR - Assessment Report

Adopted

Reference Number: EMA/303961/2016

English (EN) (537.02 KB - PDF)

**First published:** 28/04/2016

**Last updated:** 28/04/2016

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-117-epar-assessment-report_en.pdf)

Infanrix Hexa-H-C-PSUSA-00001122-201410 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

English (EN) (75.58 KB - PDF)

**First published:** 09/09/2015

**Last updated:** 09/09/2015

[View](/en/documents/scientific-conclusion/infanrix-hexa-h-c-psusa-00001122-201410-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Infanrix Hexa-H-C-296-P46-0113: EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/783377/2014

English (EN) (124.17 KB - PDF)

**First published:** 12/01/2015

**Last updated:** 12/01/2015

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-0113-epar-assessment-report_en.pdf)

Infanrix Hexa-H-C-296-P45-0089/P46-0099 : EPAR - Assessment Report

Adopted

Reference Number: EMA/409330/2014

English (EN) (92.97 KB - PDF)

**First published:** 04/11/2014

**Last updated:** 04/11/2014

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p45-0089p46-0099-epar-assessment-report_en.pdf)

Infanrix Hexa-H-C-296-P46-106.2 : EPAR - Assessment Report

Adopted

Reference Number: EMA/355024/2014

English (EN) (99.83 KB - PDF)

**First published:** 11/08/2014

**Last updated:** 11/08/2014

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-1062-epar-assessment-report_en.pdf)

Infanrix Hexa-H-C-296-P46-106.1 : EPAR - Assessment Report

Adopted

Reference Number: EMA/359928/2014

English (EN) (97.41 KB - PDF)

**First published:** 11/08/2014

**Last updated:** 11/08/2014

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-1061-epar-assessment-report_en.pdf)

Infanrix Hexa-H-C-296-P46-0110 : EPAR - Assessment Report

Adopted

Reference Number: EMA/355025/2014

English (EN) (77.17 KB - PDF)

**First published:** 11/08/2014

**Last updated:** 11/08/2014

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-0110-epar-assessment-report_en.pdf)

Infanrix Hexa-H-C-296-P46-0106 : EPAR - Assessment Report

Adopted

Reference Number: EMA/359929/2014

English (EN) (620.02 KB - PDF)

**First published:** 11/08/2014

**Last updated:** 11/08/2014

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-0106-epar-assessment-report_en.pdf-0)

Infanrix Hexa-H-C-296-P46-099.1 : EPAR - Assessment Report

Adopted

Reference Number: EMA/355023/2014

English (EN) (565.78 KB - PDF)

**First published:** 11/08/2014

**Last updated:** 11/08/2014

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-0991-epar-assessment-report_en.pdf)

Infanrix Hexa-H-C-296-P46-0106 : EPAR - Assessment Report

Adopted

Reference Number: EMA/149931/2013

English (EN) (513.39 KB - PDF)

**First published:** 26/06/2013

**Last updated:** 26/06/2013

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-0106-epar-assessment-report_en.pdf)

Infanrix Hexa-H-C-296-P46-0105 : EPAR - Assessment Report

Adopted

Reference Number: EMA/149930/2013

English (EN) (200.34 KB - PDF)

**First published:** 26/06/2013

**Last updated:** 26/06/2013

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-0105-epar-assessment-report_en.pdf)

Infanrix Hexa-H-C-296-P46-0104 : EPAR - Assessment Report

Adopted

Reference Number: EMA/149929/2013

English (EN) (564.03 KB - PDF)

**First published:** 26/06/2013

**Last updated:** 26/06/2013

[View](/en/documents/variation-report/infanrix-hexa-h-c-296-p46-0104-epar-assessment-report_en.pdf)

Infanrix Hexa : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (93.28 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/steps-after-cutoff/infanrix-hexa-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Infanrix Hexa : EPAR - Scientific Discussion

English (EN) (207.97 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/scientific-discussion/infanrix-hexa-epar-scientific-discussion_en.pdf)

Infanrix Hexa : EPAR - Procedural steps taken before authorisation

English (EN) (97.89 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/procedural-steps/infanrix-hexa-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Infanrix Hexa

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024) 28/06/2024

#### More information on Infanrix Hexa

- [Infanrix Hexa - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/infanrix-hexa)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)
- [Vaccines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A76)

**This page was last updated on** 04/09/2024

## Share this page

[Back to top](#main-content)